Importer of Controlled Substances; Notice of Application; United States Pharmacopeial Convention, 64014-64015 [2013-25073]
Download as PDF
64014
Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act [21 U.S.C.
952(a)(2)(B)] may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25062 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
emcdonald on DSK67QTVN1PROD with NOTICES
Importer of Controlled Substances,
Notice of Application, Wildlife
Laboratories, Inc.
Schedule
VerDate Mar<15>2010
17:55 Oct 24, 2013
I
Jkt 232001
Etorphine HCl (9059) ...................
II
The company plans to import the
listed controlled substances for sale to
its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act [21 U.S.C.
952(a)(2)(B)] may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
[FR Doc. 2013–25077 Filed 10–24–13; 8:45 am]
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on August 23, 2013, Wildlife
Laboratories, Inc., 1230 Wash Street,
Suite D, Windsor, Colorado 80550,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
Etorphine (except HCl) (9056) .....
Schedule
Dated: October 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Drug
Drug
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Penick
Corporation
This is notice that on February 28,
2013, Penick Corporation, 33 Industrial
Park Road, Pennsville, New Jersey
08070, made application by renewal to
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
the Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
Drug
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Poppy Straw Concentrate (9670)
Schedule
II
II
II
II
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic class of any controlled substance
in schedules I or II are, and will
continue to be, required to demonstrate
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, that the
requirements for such registration
pursuant to 21 U.S.C. 958(a); 21 U.S.C.
823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: October 17, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25064 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; United States
Pharmacopeial Convention
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on July 31, 2013, United States
Pharmacopeial Convention, 12601
Twinbrook Parkway, Rockville,
Maryland 20852, made application to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to import
reference standards for sale to
researchers and analytical labs.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedules I and II, which fall
E:\FR\FM\25OCN1.SGM
25OCN1
Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices
under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
[FR Doc. 2013–25073 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
emcdonald on DSK67QTVN1PROD with NOTICES
Importer of Controlled Substances;
Notice of Application; Noramco, Inc.
Pursuant to Title 21, Code of Federal
Regulations (CFR), 1301.34(a), this is
notice that on August 5, 2013, Noramco,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
Schedule
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
II
II
II
II
The company plans to import Opium,
raw (9600) and Poppy Straw
Concentrate (9670) to manufacture other
controlled substances. The company
plans to import Tapentadol (9780) in
intermediate form for the bulk
manufacture of Tapentadol (9780) for
distribution to its customers. The
company plans to import Phenylacetone
(8501) in bulk for the manufacture of a
controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR
3417(2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 25, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. . 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
[FR Doc. 2013–25069 Filed 10–24–13; 8:45 am]
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
By Notice dated August 2, 2013, and
published in the Federal Register on
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:55 Oct 24, 2013
Jkt 232001
64015
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Stepan
Company
By Notice dated March 19, 2013, and
published in the Federal Register on
March 28, 2013, 78 FR 19015, Stepan
Company, Natural Products Department,
100 W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Coca Leaves (9040), a
basic class of controlled substance listed
in schedule II.
The company plans to import the
listed controlled substance to
manufacture bulk controlled substance
for distribution to its customer.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR
3417(2007).
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a) and determined
that the registration of Stepan Company
to import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Stepan Company to ensure that the
company’s registration is consistent
with the public interest.
The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25087 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Importer of Controlled Substances,
Notice of Registration, Siegfried (USA),
LLC
E:\FR\FM\25OCN1.SGM
25OCN1
Agencies
[Federal Register Volume 78, Number 207 (Friday, October 25, 2013)]
[Notices]
[Pages 64014-64015]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-25073]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; United
States Pharmacopeial Convention
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on July 31, 2013, United States Pharmacopeial
Convention, 12601 Twinbrook Parkway, Rockville, Maryland 20852, made
application to the Drug Enforcement Administration (DEA) to be
registered as an importer of Noroxymorphone (9668), a basic class of
controlled substance listed in schedule II.
The company plans to import reference standards for sale to
researchers and analytical labs.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance listed in schedules I and II, which fall
[[Page 64015]]
under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i),
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than November 25, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-25073 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P